Chronic hepatitis B virus (HBV) infection is a common cause of liver disease globally, with a
disproportionately high burden in South-East Asia. Vaccines and nucleoside or nucleotide …

Viral hepatitis is a major public health threat and a leading cause of death worldwide.
Annual mortality from viral hepatitis is similar to that of other major infectious diseases such …

The COVID-19 pandemic has spread rapidly worldwide. It is common to encounter patients
with COVID-19 with abnormal liver function, either in the form of hepatitis, cholestasis, or …

We previously identified the major pathological changes in the respiratory and immune
systems of patients who died of severe acute respiratory syndrome (SARS) but gained little …

Detection of asymptomatic or subclinical novel human coronavirus SARS-CoV-2 infection is
critical for understanding the overall prevalence and infection potential of COVID-19. To …

Hepatitis B is one of the most common infectious diseases globally. It has been estimated
that there are 350 million chronic hepatitis B virus (HBV) carriers worldwide. The prevalence …

Background & Aims Hepatitis B virus (HBV) RNA in serum has recently been linked to
efficacy and prognosis of chronic hepatitis B (CHB) treatment. This study explored the …

Chronic hepatitis B and its life‐threatening sequelae are highly prevalent in China. There is
a need for effective new therapies to suppress hepatitis B virus (HBV) replication and …

Background & Aims Hepatocellular carcinoma (HCC) is the leading cause of death in
patients with chronic hepatitis. In this international collaboration, we sought to develop a …

Background & Aims Durable post-treatment response is uncommon in chronic hepatitis B
(CHB) patients on nucleos (t) ide analogue therapy. Response, response predictors and …